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General Experimental
All reactions were carried out employing standard chemical techniques under inert atmosphere. Solvents used for extraction, washing, and chromatography were HPLC grade. Unless otherwise noted, all reagents were purchased from Aldrich Chemical Co. and were used without further purification. Analytical thin layer chromatography was performed on 250 µm silica gel plates from Sorbent Technologies. Analytical HPLC was performed on an Agilent 1200 LCMS with UV detection at 215 nm and 254 nm along with ELSD detection and electrospray ionization, with all final compounds showing > 95% purity and a parent mass ion consistent with the desired structure. All NMR spectra were recorded on a 400 MHz Brüker AV-400 instrument. 1 H chemical shifts are reported as δ values in ppm relative to the residual solvent peak S2 (MeOD = 3.31, CDCl 3 = 7.26). Data are reported as follows: chemical shift, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet), coupling constant (Hz), and integration. 13 C chemical shifts are reported as δ values in ppm relative to the residual solvent peak (MeOD = 49.0, CDCl 3 = 77.16). Low resolution mass spectra were obtained on an Agilent 1200 LCMS with electrospray ionization. High resolution mass spectra were recorded on a Waters QToF-API-US plus Acquity system with electrospray ionization. Automated flash column chromatography was performed on a Teledyne ISCO Combiflash Rf system. Preparative purification of library compounds was performed on a Gilson 215 preparative LC system. Optical rotations were acquired on a Jasco P-2000 polarimeter at 23
°C and 589 nm. The specific rotations were calculated according to the equation [α]
where l is path length in decimeters and c is the concentration in g/100 mL.
In vitro pharmacology methods

Calcium mobilization assays:
All functional cell-based assays were performed on a FLEXStationII (Molecular Devices) essentially as previously described (Marlo et al., 2009; Brady et al., 2008; Gentry et al., 2013) . Initial, single point (10 µM) PAM characterization was performed in stable Chinese hamster ovary (CHO) cell lines constitutively expressing human M 5 receptors. These were plated at 50,000 cells per well in Costar 96well black-walled, TC-treated, clear-bottomed plates (Fisher) in Ham's F12 medium supplemented with 10% FBS and 20 mM HEPES. Cells were incubated overnight at 37 °C under 5% CO 2 . The following day, medium was removed and replaced with 50 µL of 2 µM Fluo-4 AM (Invitrogen) in calcium assay buffer (Hank's Balanced Salt Solution supplemented with 20 mM HEPES and 2.5 mM Probenecid, pH 7.4) and the cells were then incubated 45 minutes at 37 °C under 5% CO 2 . Dye was then removed and replaced with 45 µL of fresh assay buffer. Test compounds were serially diluted into assay buffer to a 2X (20 µM) stock concentration in 0.6% dimethylsulfoxide (DMSO); stock compounds were added to the assay for a final stock concentration of 10 µM and a final DMSO concentration of 0.3%. Acetylcholine (Sigma-Aldrich) was serial diluted into assay buffer to 10X submaximal (~EC 20 , determined empirically) and 10X maximal (10 µM) stock concentrations. After establishing baseline fluorescence, test compounds (45 µL) were added to the cells using the FLEXstation II's integrated pipettor and allowed to equilibrate for 150 seconds before addition of the EC 20 (10 µL). Data were obtained as max-min fluorescent ratios and then normalized to percentage of maximal acetylcholine response. The single point values represent mean values obtained from at least three independent determinations performed in triplicate or greater (error bars represent +/-SEM) unless otherwise specified.
For Ca 2+ mobilization assays measuring acetylcholine CRC fold shift, CHO cells stably expressing hM 5 were plated in the manner described above. Test compounds were serially diluted into assay buffer to a 2X (20 µM) stock concentration in 0.6% dimethylsulfoxide (DMSO); stock compounds were added to the assay for a final stock concentration of 10 µM and a final DMSO concentration of 0.3%. An eight-point concentration range of acetylcholine was serial diluted in assay buffer to 10X final concentration. FLEXstation II protocols were carried out as described above; data were obtained as max-min fluorescent ratios and then normalized to percentage of maximum acetylcholine response. Calculation of acetylcholine EC 50 was performed using the curve-fitting software of GraphPad Prism (version 5.01). Acetylcholine fold shift was calculated as a ratio of ACh EC 50 in the presence of vehicle to the ACh EC 50 in the presence of test compound. Data shown represent mean values obtained from at least three independent determinations performed in triplicate or greater (error bars represent ± SEM) unless otherwise specified.
For muscarinic selectivity assays, CHO cells stably expressing hM 1 , hM 2 /G qi5 , hM 3 , hM 4 /G qi5 , hM 5 , rM 1 , rM 2 /G qi5 , rM 3 , rM 4 /G qi5 , or rM 5 were plated in the manner described above. An eight-point concentration range of test compound was serially diluted in assay buffer to 2X final concentration and acetylcholine was diluted in assay buffer to 10X submaximal (~EC 20 , determined empirically) and 10X maximal (10 µM for M 1 , M 3 , & M 5 ; 100 µM for M 2 & M 4 ) stock concentrations. FLEXstation II protocols were carried out as described above; data were obtained as max-min fluorescent ratios and then normalized to percentage of maximum acetylcholine response. Calculation of EC 50 was performed using the curvefitting software of GraphPad Prism (version 5.01). Data shown represent mean values obtained from at least three independent determinations performed in triplicate or greater (error bars represent ± SEM) unless otherwise specified.
[ 3 H]-NMS Competition Binding Assay:
Membranes were prepared from stable CHO cell lines constitutively expressing human M 5 receptors according to previously described protocols (Marlo et al., 2009; Brady et al., 2008; Gentry et al., 2013) . For inhibition binding experiments, reactions were carried out in 2 mL, clear, 96-well, deep well plates (Axygen Scientific) and contained 0.3 nM [ 3 H]-N-methylscopolamine ([ 3 H]-NMS, obtained commercially from PerkinElmer), 10 µg of membrane protein, and an 11 point concentration range of test compound or atropine in a total volume of 500 µL assay buffer (100 mM NaCl, 10 mM MgCl 2 , 20 mM HEPES, pH 7.4). For acetylcholine affinity experiments, reactions were carried out in the same deep well plates with 0.4 nM [ 3 H]NMS, 10 µg of membrane protein, fixed concentrations of test compound (300 nM-10 µM), a 10 point concentration of acetylcholine or vehicle, and 100 µM Gpp(NH)p in a total volume of 500 µL of assay buffer. Nonspecific binding was determined in the presence of 10 µM atropine. The K D of [ 3 H]-NMS was determined empirically to be 0.264 nM. Binding reactions were performed at ambient temperature and allowed to incubate for 3 hours on a Lab-Line Titer plate shaker at setting 7 (~750 rpm). Reactions were terminated by rapid filtration through GF/B filter plates (1 µm pore size) using a 96-well Brandel harvester and washed 3X with ice-cold harvesting buffer (50 mM Tris-HCl, 0.9% NaCl, pH 7.4). Filter plates were dried overnight and counted in a PerkinElmer TopCount scintillation counter (PerkinElmer Life and Analytical Sciences). Actual [ 3 H]-NMS concentration was back-calculated after counting aliquots of 10X [ 3 H]-NMS used in the reaction. Atropine K i was determined to be ~1.47 nM. For all assays, radioligand depletion was kept to approximately 15% or less. Data was plotted and atropine K i was calculated using the curve-fitting software of GraphPad Prism (version 5.01). Data shown represent mean values obtained from three independent determinations performed using three or more replicates (error bars represent +/-SEM).
S4
DMPK Methods
Plasma protein and brain homogenate binding:
The degree of plasma protein binding of each test compound was determined essentially as previously described (Gentry et al., 2013) . The protein binding of each compound was determined in plasma via equilibrium dialysis employing RED Plates (ThermoFisher Scientific, Rochester, NY). Plasma was added to the 96 well plate containing test compound and mixed thoroughly for a final compound concentration of 5 µM. Subsequently, an aliquot of the plasma-compound mixture was transferred to the cis chamber (red) of the RED plate, with a phosphate buffer (25 mM, pH 7.4) in the trans chamber. The RED plate was sealed and incubated for 4 hours at 37°C with shaking. At completion, aliquots from each chamber were diluted 1:1 with either plasma (cis) or buffer (trans) and transferred to a new 96 well plate, at which time ice-cold acetonitrile containing internal standard (50 ng/mL carbamazepine) (2 volumes) was added to extract the matrices. The plate was centrifuged (3000 rcf, 10 min) and supernatants transferred and diluted 1:1 (supernatant: water) into a new 96 well plate, which was then sealed in preparation for LC/MS/MS analysis. Each compound was assayed in triplicate within the same 96-well plate. Fraction unbound was determined using the following equation: plasma buffer u Conc Conc F = A similar approach was used to determine the degree of brain homogenate binding, which employed the same methodology and procedure with the following modifications: 1) a final compound concentration of 1 µM was used, 2) naïve rat brains were homogenized in DPBS (1:3 composition of brain:DPBS, w/w) using a Mini-Bead Beater machine in order to obtain brain homogenate, which was then utilized in the same manner as plasma in the previously described plasma protein binding assay. Fraction unbound was determined using the following equation:
Intrinsic clearance:
The intrinsic clearance of each test compound was determined essentially as previously described (Gentry et al., 2013) . Human or rat hepatic microsomes (0.5 mg/mL) and 1 µM test compound were incubated in 100 mM potassium phosphate pH 7.4 buffer with 3 mM MgCl 2 at 37 °C with constant shaking. After a 5 min preincubation, the reaction was initiated by addition of NADPH (1 mM). At selected time intervals (0, 3, 7, 15, 25, and 45 min), aliquots were taken and subsequently placed into a 96-well plate containing cold acetonitrile with internal standard (50 ng/mL carbamazepine). Plates were then centrifuged at 3000 rcf (4° C) for 10 min, and the supernatant was transferred to a separate 96-well plate and diluted 1:1 with water for LC/MS/MS analysis. The in vitro half-life (T 1/2 , min, Eq. 1), intrinsic clearance (CL int , mL/min/kg, Eq. 2) and subsequent predicted hepatic clearance (CL hep , mL/min/kg, Eq. 3) was determined employing the following equations:
(1) where Q h (hepatic blood flow, mL/min/kg) is 21 (human) or 70 (rat).
LC/MS/MS Bioanalysis of Samples from Plasma Protein Binding and Intrinsic Clearance Assays:
Samples were analyzed essentially as previously described (Gentry et al., 2013) on a Thermo Electron TSQ Quantum Ultra triple quad mass spectrometer (San Jose, CA) via electrospray ionization (ESI) with two Themo Electron Accella pumps (San Jose, CA), and a Leap Technologies CTC PAL autosampler (Carrboro, NC). Analytes were separated by gradient elution on a dual column system with two Thermo Hypersil Gold (2.1 x 30 mm, 1.9 µm) columns (San Jose, CA) thermostated at 40°C. HPLC mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in acetonitrile. The gradient started at 10% B after a 0.2 min hold and was linearly increased to 95% B over 0.8 min; hold at 95% B for 0.2 min; returned to 10% B in 0.1 min. The total run time was 1.3 min and the HPLC flow rate was 0.8 mL/min. While pump 1 ran the gradient method, pump 2 equilibrated the alternate column isocratically at 10% B. Compound optimization, data collection and processing was performed using Thermo Electron's QuickQuan software (v2.3) and Xcalibur (v2.0.7 SP1).
In vivo DMPK experimental:
Plasma pharmacokinetics (PK) of compound 8n (VU481443) rat were obtained via contract with Frontage Laboratories (Exton, PA). Serial sampling of plasma (10 time points) following a single intravenous administration (1 mg/kg; formulated at 1 mg/mL in 10% EtOH 50% PEG400 40% saline) to male Sprague-Dawley rats (n = 3) was performed in order to obtain PK parameters (non-compartmental analysis). After 24 hr, re-administration of the same dose (and formulation) was performed, and single time point (0.25 hr post-re-administration) samples of plasma and brain were collected in order to assess brain distribution (brain:plasma partition coefficient, K p ). In vivo samples were analyzed via LC/MS/MS utilizing electrospray ionization (ESI) and MRM transition(s) specific to the analyte.
Animal care and use:
All animal study procedures were approved by the Institutional Animal Care and Use Committee and were conducted in accordance with the National Institutes of Health regulations of animal care covered in Principles of Laboratory Animal Care (National Institutes of Health).
Chemical Experimentals & Characterization tert-butyl 4-(benzylcarbamoyl)piperidine-1-carboxylate(3).
To a solution of 1-tertbutoxycarbonylpiperidine-4-carboxylic acid (600 mg, 2.62 mmol, 1.0 eq.; Oakwood company, No. 019200, Lot No. F23F), benzylamine (273 µL, 3.93 mmol, 1.5 eq.), and DIPEA (898 µL, 5.24 mmol, 2.0 eq.) in DCM (10 mL, 0.26 M) was added HATU (1.99 g, 5.24 mmol, 2.0 eq.; Oakwood company, No. 023926, Lot No. G02L). The reaction was magnetically stirred at ambient temperature for 4 hours. The reaction was quenched with saturated aqueous NaHCO 3 and the phases were separated. The aqueous layer was extracted with DCM. The combined organic layers were then washed with brine and dried over MgSO 4 . Following filtration, the solvent was removed under reduced pressure. Crude product was purified via automated silica gel flash chromatography. Product containing fractions were combined and the solvents removed under reduced pressure to obtain 834 mg of product (99% yield). TLC R f = 0.52 (hexane/ethyl acetate 1:1, p-anisaldehyde stain). 1 H NMR (~1:1 rotamer ratio, asterisk denotes rotamer peak, 400.1 MHz, CDCl 3 ) δ (ppm): 7.35-7.22 (m, 5H); 5.83 (br, 1H); 4.44*, 4.42* (s, 2H); 4.20-4.08 (m, 2H); 2.79-2.66 (m, 2H); 2.30-2.20 (m, 1H); 1.87-1.78 (m, 2H); 1.71-1.59 (m, 2H); 1.45 (s, 9H). 13 C NMR (100.6 MHz, CDCl 3 ) δ (ppm): 174.29, 154.78, 138.34, 128.89, 127.87, 127.72, 79.75, 43.65, 43.49, 28.79, 28.56 1-carboxylate(4) . To a solution of tert-butyl 4-(benzylcarbamoyl)piperidine-1-carboxylate (700 mg, 2.20 mmol, 1.0 eq.) in THF (10 mL, 0.22 M) was added NaO t Bu (254 mg, 2.64 mmol, 1.2 eq.) and 15-crown-5 (524 µL, 2.64 mmol, 1.2 eq.). The reaction was magnetically stirred at ambient temperature for 30 minutes at which time ethyl iodide (355 µL, 4.40 mmol, 2.0 eq.) was added to the reaction mixture. The reaction was then magnetically stirred at ambient temperature for 3 hours. The reaction was quenched with water and the phases were separated. The aqueous layer was extracted with ethyl acetate. The combined organic layers were then washed with brine and dried over MgSO 4 . Following filtration, the solvent was removed under reduced pressure. Crude product was purified via automated silica gel flash chromatography. Product containing fractions were combined and the solvents removed under reduced pressure to obtain 596 mg of product (78% yield). TLC R f = 0.64 (hexane/ethyl acetate 1:1, p-anisaldehyde stain). 1 H NMR (1.4:1 rotamer ratio, asterisk denotes minor rotamer peaks, 400.1 MHz, CDCl 3 ) δ (ppm): 7.39-7.11 (m, 5H); 4.58, 4.55* (s, 2H); 4.26-4.02 (m, 2H); 3.40*, 3.28 (q, J = 7.1 Hz, 2H); 2.85-2.49 (m, 3H); 1.90-1.55 (m, 4H); 1.45, 1.43* (s, 9H); 1.15, 1.08* (t, J = 7.1 Hz, 3H). 13 C NMR (1.5:1 rotamer ratio, asterisk denotes minor rotamer peaks, 100.6 MHz, CDCl 3 ) δ (ppm): 174.78 *, 174.64, 154.78, 138.02, 137.35*, 129.04*, 128.66, 127.90, 127.74*, 127.34, 126.26*, 79.64, 79.59*, 50.46*, 47.79, 43.38, 41.40, 41.16*, 39.09*, 38.87, 28.88, 28.71*, 28.54, 14.54, 12. 
tert-butyl 4-(benzyl(ethyl)carbamoyl)piperidine-
N-benzyl-N-ethylpiperidine-4-carboxamide HCl(5)
. tert-butyl 4-(benzyl(ethyl)carbamoyl)piperidine-1carboxylate (500 mg, 1.44 mmol, 1.0 eq.) was dissolved neat in 4N HCl/dioxane. The reaction was magnetically stirred at ambient temperature for 1 hour. Solvent was then removed under reduced pressure to obtain 407 mg of product (quantitiative yield). TLC R f = 0.01 (hexane/ethyl acetate 1:1, p-anisaldehyde stain). 1 H NMR (1.3:1 rotamer ratio, asterisk denotes minor rotamer peaks, 400.1 MHz, MeOD) δ (ppm): 7.33-7.09 (m, 5H); 4.63*, 4.50 (s, 2H); 3.41-3.25 (m, 4H); 3.21 (quint, J = 1.6 Hz, 1H); 3.11-2.84 (m, 3H); 1.97-1.70 (m, 4H), 1.10, 1.00* (t, J = 7.1, 3H). 13 C NMR (1.5:1 rotamer ratio, asterisk denotes minor rotamer peaks, 100.6 MHz, MeOD) δ (ppm): 175.67 *, 175.60, 138.90, 138.65*, 129.99*, 129.64, 128.71*, 128.62, 128.37, 127.68*, 51.79, 44.28, 44.19*, 43.25, 42.84*, 37.30*, 36.93, 26.94, 26.75*, 14.73, 12. N-benzyl-1-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-N-ethylpiperidine-4-carboxamide (1) . To a solution of N-benzyl-N-ethylpiperidine-4-carboxamide HCl (20 mg, 0.071 mmol, 1.0 eq.) and DIPEA (74 µL, 0.213 mmol, 3.0 eq.) in DCM (1 mL, 0.071 M) was added 1,4-benzodioxan-6-sulfonyl chloride (25 mg, 0.107 mmol, 1.5 eq.). The reaction was magnetically stirred at ambient temperature for 2 hours. The reaction was quenched with saturated aqueous NaHCO 3 and the phases were separated. The aqueous layer was extracted with DCM. The combined organic layers were then washed with brine and dried over MgSO 4 . Following filtration, the solvent was removed under reduced pressure. Crude product was purified via Gilson preparative LC to obtain 26 mg pure product (84% yield). TLC R f = 0.64 (hexane/ethyl acetate 1:1). 1 H NMR (1.3:1 rotamer ratio, asterisk denotes minor rotamer peaks, 400.1 MHz, CDCl 3 ) δ (ppm): 7.38-6.89 (m, 8H); 4.55, 4.48* (s, 2H); 4. 35-4.24 (m, 4H) ; 3.84-3.67 (m, 2H); 3.37*, 3.21 (q, J = 7.1 Hz, 2H); 2.51-2.22 (m, 3H), 2.08-1.88 (m, 2H), 1.84-1.65 (m, 2H), 1.15-1.02 (m, 3H). 13 C NMR (1.2:1 rotamer ratio, asterisk denotes minor rotamer peaks, 100.6 MHz, CDCl 3 ) δ (ppm): 174.17*, 174.05, 147.56, 143.66*, 137.86, 137.07*, 129.08*, 128.82*, 128.71, 128.67*, 127.93, 127.79, 127.43, 126.13*, 121.52, 121.47*, 117.80, 117.38, 117.33*, 64.64, 64.29, 50.34*, 47.83, 45.68, 45.61*, 41.38, 41.15*, 37.98*, 37.78, 28. 46, 28.33*, 14.52, 12.76 4-((1-phenylethyl) carbamoyl)piperidine-1-carboxylate. To a solution of 1-tertbutoxycarbonylpiperidine-4-carboxylic acid (500 mg, 2.18 mmol, 1.0 eq.; Oakwood company, No. 019200, Lot No. F23F), (R)-(+)-α-methylbenzylamine (334 µL, 2.62 mmol, 1.2 eq.), and DIPEA (747 µL, 4.36 mmol, 2.0 eq.) in DCM (10 mL, 0.22 M) was added HATU (1.04 g, 2.73 mmol, 1.25 eq.; Oakwood company, No. 023926, Lot No. G02L). The reaction was magnetically stirred at ambient temperature for 4 hours. The reaction was quenched with saturated aqueous NaHCO 3 and the phases were separated. The aqueous layer was extracted with DCM. The combined organic layers were then washed with brine and dried over MgSO 4 . Following filtration, the solvent was removed under reduced pressure. Crude product was purified via automated silica gel flash chromatography. Product containing fractions were combined and the solvents removed under reduced pressure to obtain 584 mg of product (81% yield). TLC R f = 0.52 (hexane/ethyl acetate 1:1, p-anisaldehyde stain). 1 H NMR (~1:1 rotamer ratio, asterisk denotes rotamer peak, 400.1 MHz, CDCl 3 ) δ (ppm): 7.38-7.22 (m, 5H); 5.70 (br, 1H); 5.12 (quint, J = 7.2 Hz, 1H); 4.12 (br, 2H); 2.79-2.64 (m, 2H); 2.27-2.15 (m, 1H); 1.85-1.73 (m, 2H); 1.70-1.54 (m, 2H); 1.49*, 1.47* (s, 3H); 1.45 (s, 9H). 13 C NMR (100.6 MHz, CDCl 3 ) δ (ppm): 173.47, 154.80, 143.24, 128.86, 127.56, 126.22, 79.74, 48.67, 43.51, 28.78, 28.73, 28.56, 21.82 (1-phenylethyl) carbamoyl)piperidine-1-carboxylate. To a solution of (R)-tertbutyl 4-((1-phenylethyl)carbamoyl)piperidine-1-carboxylate (100 mg, 0.301 mmol, 1.0 eq.) in THF (2 mL, 0.15 M) was added NaO t Bu (43 mg, 0.451 mmol, 1.5 eq.) and 15-crown-5 (90 µL, 0.451 mmol, 1.5 eq.). The reaction was magnetically stirred at ambient temperature for 30 minutes at which time ethyl iodide (49 µL, 0.602 mmol, 2.0 eq.) was added to the reaction mixture. The reaction was then magnetically stirred at ambient temperature for 24 hours. The reaction was quenched with water and the phases were separated. The aqueous layer was extracted with DCM. The combined organic layers were then washed with brine and dried over MgSO 4 . Following filtration, the solvent was removed under reduced pressure. Crude product was purified via automated silica gel flash chromatography. Product containing fractions were combined and the solvents removed under reduced pressure to obtain 27 mg of product (25% yield). TLC R f = 0.65 (hexane/ethyl acetate 1:1, p-anisaldehyde stain). 1 H NMR (~2:1 rotamer ratio, asterisk denotes minor rotamer peaks, 400.1 MHz, CDCl 3 ) δ (ppm): 7.40-7.18 (m, 5H); 6.04, 5.13* (q, J = 6.9 Hz, 1H); 4.18 (br, 2H); 3.52-2.86 (m, 2H); 2.86-2.48 (m, 3H); 1.95-1.73 (m, 2H); 1.72-1.57 (m, 3H); 1.56-1.49 (m, 2H); 1.48-1.38* (m, 9H); 1.03*, 0.98 (t, J = 6.9, 3H). 13 C NMR (~2:1 rotamer ratio, asterisk denotes minor rotamer peaks, 100.6 MHz, CDCl 3 ) δ (ppm): 174.96, 174.46*, 154.82, 141.38, 141.05*, 128.85*, 128.51, 127.65*, 127.51, 127.39, 126.60*, 79.70, 79.64*, 54.98*, 50.73, 39.73, 39.50*, 38.58*, 37.91, 29.12, 29.08*, 28.83*, 28.76, 28.57, 19.20*, 17.27, 16.94, 14. 
(R)-tert-butyl
(R)-tert-butyl 4-(ethyl
(R)-N-ethyl-N-(1-phenylethyl)piperidine-4-carboxamide
HCl.
(R)-tert-butyl 4-(ethyl(1phenylethyl)carbamoyl)piperidine-1-carboxylate (347 mg, 0.963 mmol, 1.0 eq.) was dissolved neat in 4N HCl/dioxane. The reaction was magnetically stirred at ambient temperature for 1 hour. Solvent was then removed under reduced pressure to obtain 255 mg of product (89% yield). TLC R f = 0.01 (hexane/ethyl acetate 1:1, p-anisaldehyde stain). 1 H NMR (1.5:1 rotamer ratio, asterisk denotes minor rotamer peaks, 400.1 MHz, MeOD) δ (ppm): 7.43-7.24 (m, 5H); 5.86, 5.38* (q, J = 7.1 Hz, 1H); 3.51-2.93 (m, 7H); 2.08-1.87 (m, 4H); 1.70*, 1.55 (d, J = 7.0 Hz, 3H); 0.99, 0.97* (t, J = 7.1 Hz, 3H). 13 C NMR (1.5:1 rotamer ratio, asterisk denotes minor rotamer peaks, 100.6 MHz, MeOD) δ (ppm): 175.78, 175.29*, 142.02, 129.82*, 129.59, 128.75*, 128.60, 128.45, 127.97*, 56.66*, 53.02, 44.31*, 44.28, 39.58*, 39.41, 37.80, 37.47*, 27.12*, 27.06, 26.99*, 26.88, 19.20*, 17.17, 17.12, 14.52 
(R)-1-((1H-indazol-5-yl)sulfonyl)-N-ethyl-N-(1-phenylethyl)piperidine-4-carboxamide (7g).
To a solution of (R)-N-ethyl-N-(1-phenylethyl)piperidine-4-carboxamide HCl (20 mg, 0.067 mmol, 1.0 eq.) and DIPEA (23 µL, 0.134 mmol, 2.0 eq.) in DCM (0.7 mL, 0.1 M) was added 1H-indazole-5-sulfonyl chloride (22 mg, 0.101 mmol, 1.5 eq.). The reaction was magnetically stirred at ambient temperature for 2 hours. The reaction was quenched with saturated aqueous NaHCO 3 and the phases were separated. The aqueous layer was extracted with DCM. The combined organic layers were then washed with brine and dried over MgSO 4 . Following filtration, the solvent was removed under reduced pressure. Crude product was purified via Gilson preparative LC to obtain 26 mg pure product (88% yield). TLC R f = 0.23 (hexane/ethyl acetate 1:1). 1 H NMR (1.7:1 rotamer ratio, asterisk denotes minor rotamer peaks, 400.1 MHz, CDCl 3 ) δ (ppm): 8. 32-8.17 (m, 2H); 7.79-7.56 (m, 2H); 7.35-7.10 (m, 5H) ; 5.99, 5.00* (q, J = 7.1 Hz, 1H); 3.96-3.76 (m, 2H), 3.50-2.80 (m, 2H), 2.57-2.30 (m, 3H); 2.12-1.88 (m, 2H); 1.85-1.69 (m, 2H); 1.60*, 1.47 (d, J = 7.1 Hz, 3H); 0.99*, 0.87 (t, J = 7.1, 3H). 13 C NMR (1.7:1 rotamer ratio, asterisk denotes minor rotamer peaks, 100.6 MHz, CDCl 3 ) δ (ppm): 174.47, 173.94*, 141.40, 140.64*, 136.20, 129.41, 129.26*, 128.88*, 128.57, 127.75*, 127.52, 127.49, 126.49, 125.46, 122.80, 110.76, 55.06*, 50.98, 45.71, 38.65*, 38.55, 38.34*, 37.97, 28.66*, 28.41, 19.15*, 17.18, 16.92, 14.51 4-((2-(trifluoromethyl) benzyl)carbamoyl)piperidine-1-carboxylate. To a solution of 1-tertbutoxycarbonylpiperidine-4-carboxylic acid (573 mg, 2.5 mmol, 1.0 eq.; Oakwood company, No. 019200, Lot No. F23F), 2-(trifluoromethyl)benzylamine (421 µL, 3 mmol, 1.2 eq.), and DIPEA (857 µL, 5 mmol, 2.0 eq.) in DCM (12 mL, 0.21 M) was added HATU (1.43 g, 3.75 mmol, 1.5 eq.; Oakwood company, No. 023926, Lot No. G02L). The reaction was magnetically stirred at ambient temperature for 24 hours. The reaction was quenched with saturated aqueous NaHCO 3 and the phases were separated. The aqueous layer was extracted with DCM. The combined organic layers were then washed with brine and dried over MgSO 4 . Following filtration, the solvent was removed under reduced pressure. Crude product was purified via automated silica gel flash chromatography. Product containing fractions were combined and the solvents removed under reduced pressure to obtain 607 mg of product (63% yield). TLC R f = 0.55 (hexane/ethyl acetate 1:1 4-(ethyl(2-(trifluoromethyl)benzyl) carbamoyl)piperidine-1-carboxylate. To a solution of tert-butyl 4-((2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-carboxylate (394 mg, 1.020 mmol, 1.0 eq.) in THF (6.8 mL, 0.15 M) was added NaO t Bu (147 mg, 1.529 mmol, 1.5 eq.) and 15-crown-5 (405 µL, 2.039 mmol, 2 eq.). The reaction was magnetically stirred at ambient temperature for 30 minutes at which time ethyl iodide (164 µL, 2.0392 mmol, 2.0 eq.) was added to the reaction mixture. The reaction was then magnetically stirred at ambient temperature overnight. The reaction was quenched with brine and the phases were separated. The aqueous layer was extracted with EtOAc. The combined organic layers were then dried over MgSO 4 . Following filtration, the solvent was removed under reduced pressure. Crude product was purified via automated silica gel flash chromatography. Product containing fractions were combined and the solvents removed under reduced pressure to obtain 350 mg of product (83% yield). TLC R f = 0.69 (hexane/ethyl acetate 1:1, UV-Vis). 1 H NMR (~1:1 rotamer ratio, asterisk denotes rotamer peak, 400.1 MHz, CDCl 3 ) δ (ppm): 7.75-7.18 (m, 4H); 4.80*, 4.72* (s, 2H); 4.28-4.03 (m, 2H); 3.45*, 3.31* (q, J = 7.3 Hz, 2H); 2.87-2.30 (m, 3H); 1.94-1.51 (m, 4H); 1.46*, 1.43* (s, 9H); 1.18*, 1.13* (t, J = 7.1 Hz, 3H). 13 C NMR (~1:1 rotamer ratio, asterisk denotes rotamer peak, 100.6 MHz, CDCl 3 ) δ (ppm): 175.15, 154.83*, 154.76*, 136.76*, 136.39*, 132.67*, 132.30*, 128.30 (q, J CF = 30.7 Hz), 128.11*, 127.77*, 127.15*, 126.65*, 126.62*, 125 .97* (q, J CF = 5.4 Hz), 124.44*, 124.50* (q, J CF = 273.5 Hz), 79.77*, 79.65*, 46.98*, 44.02*, 43.39; 42.05*, 41.88*, 39.20*, 38.87*, 28.93*, 28.65*, 28.58*, 28.55*, 14.53*, 12.79 
tert-butyl
N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide
HCl. tert-butyl 4-(ethyl(2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-carboxylate (297 mg, 0.717 mmol, 1.0 eq.) was dissolved neat in 4N HCl/dioxane. The reaction was magnetically stirred at ambient temperature for 1 hour. Solvent was then removed under reduced pressure to obtain 247 mg of product (98% yield). TLC R f = 0.01 (hexane/ethyl acetate 1:1, p-anisaldehyde stain). 1 H NMR (~2.5:1 rotamer ratio, asterisk denotes minor rotamer peaks, 400.1 MHz, MeOD) δ (ppm): 7.82-7.22 (m, 4H); 4.88*, 4.79 (s, 2H); 3.54-3.36 (m, 4H); 3.25-3.11 (m, 2H); 3.01-2.82 (m, 1H); 2.14-1.86 (m, 4H); 1.22, 1.12* (t, J = 7.2 Hz, 3H). 13 C NMR (2.5:1 rotamer ratio, asterisk denotes minor rotamer peaks, 100.6 MHz, MeOD) δ (ppm): 176. 09, 175.85*, 137.17, 137.07*, 134.08*, 133.61, 129.21*, 128.96 (q, J CF = 30.7 Hz), 128.77, 128.58, 128.40*, 127.6*, 127 .13 (q, J CF = 5.6 Hz), 126.10 (q, J CF = 272.6 Hz), 126.02 *, 45.93*, 45.89, 44.28, 44.12*, 43.83, 42.98*, 37.20*, 36.88, 26.94, 26.70*, 14.62, 12.63 1-((1H-indazol-5-yl)sulfonyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (8n,  ML380) . To a solution of N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide HCl (20 mg, 0.063 mmol, 1.0 eq.) and DIPEA (33 µL, 0.196 mmol, 2.0 eq.) in DCM (0.7 mL, 0.1 M) was added 1H-
